TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer
Brief Summary: This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of IRIS, and feasibility of FOLFIRI. Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with FOLFIRI.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CPT-11 and TS-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: CPT-11, 5-FU and l-LV | Intervention Type: DRUG; Name: CPT-11 and TS-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CPT-11, 5-FU and l-LV; Assigned to Arm(s): 2
B: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI
C: Arm Label: FOLFOX4; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil (5-FU), Drug: Leucovorin calcium, Drug: Oxaliplatin | Arm Label: FOLFOX4 + Bv; Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: 5-Fluorouracil (5-FU), Drug: Leucovorin calcium, Drug: Oxaliplatin | Arm Label: XELOX+Bv; Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Capecitabine, Drug: Oxaliplatin | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): FOLFOX4 + Bv, XELOX+Bv | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): XELOX+Bv | Intervention Type: DRUG; Name: 5-Fluorouracil (5-FU); Assigned to Arm(s): FOLFOX4, FOLFOX4 + Bv | Intervention Type: DRUG; Name: Leucovorin calcium; Assigned to Arm(s): FOLFOX4, FOLFOX4 + Bv | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): FOLFOX4, FOLFOX4 + Bv, XELOX+Bv
D: Arm Label: 5-Fluorouracil (5-FU); Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU | Arm Label: Capecitabine; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine | Intervention Type: DRUG; Name: 5-FU; Assigned to Arm(s): 5-Fluorouracil (5-FU)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer
Brief Summary: This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of IRIS, and feasibility of FOLFIRI. Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with FOLFIRI.


Options:
A: Arm Label: Regorafenib (Stivarga, BAY73-4506)+BSC; Type: EXPERIMENTAL; Interventions: Drug: Regorafenib (Stivarga, BAY73-4506), Other: Best Supportive Care (BSC) | Arm Label: Placebo+BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Regorafenib (Stivarga, BAY73-4506); Assigned to Arm(s): Regorafenib (Stivarga, BAY73-4506)+BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+BSC | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo+BSC, Regorafenib (Stivarga, BAY73-4506)+BSC
B: Arm Label: FOLFIRI +/- Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Drug: CPT-11 (Irinotecan), Drug: 5-FU Bolus, Drug: 5-FU Infusion, Drug: l-LV (dl-LV) | Arm Label: XELIRI +/- Bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: CPT-11 (Irinotecan), Drug: Capecitabine | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Bolus; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Infusion; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: l-LV (dl-LV); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): XELIRI +/- Bevacizumab
C: Arm Label: Cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetuximab | Arm Label: Panitumumab; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Cetuximab | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CPT-11 and TS-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: CPT-11, 5-FU and l-LV | Intervention Type: DRUG; Name: CPT-11 and TS-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CPT-11, 5-FU and l-LV; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of a Worksite Based Walking Programme on Cardiovascular Risk in Previously Sedentary Civil Servants
Brief Summary: The purpose of this study was to investigate the effects of an 8 week program of walking for 45 minutes, twice a week, on fitness, body composition , blood pressure and blood markers of cardiovascular risk. We hypothesised that this 90 minutes of walking per week would result in measurable increases in fitness and reductions in body fat, resting blood pressure and improved blood lipid profiles.


Options:
A: Arm Label: The experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Group walking and group educational workshops | Arm Label: The control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group walking and group educational workshops; Assigned to Arm(s): The experimental group
B: Arm Label: Resistance Training; Type: EXPERIMENTAL; Interventions: Behavioral: Resistance Training | Arm Label: Aerobic Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise | Arm Label: Combination RT & AT; Type: EXPERIMENTAL; Interventions: Behavioral: Combo | Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: Continued Sedentary lifestyle | Intervention Type: BEHAVIORAL; Name: Resistance Training; Assigned to Arm(s): Resistance Training | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise; Assigned to Arm(s): Aerobic Exercise | Intervention Type: BEHAVIORAL; Name: Combo; Assigned to Arm(s): Combination RT & AT | Intervention Type: BEHAVIORAL; Name: Continued Sedentary lifestyle; Assigned to Arm(s): Control
C: Arm Label: pedometer-plus-email; Type: EXPERIMENTAL; Interventions: Behavioral: pedometer-plus-email | Arm Label: pedometer-only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: pedometer-only | Intervention Type: BEHAVIORAL; Name: pedometer-plus-email; Assigned to Arm(s): pedometer-plus-email | Intervention Type: BEHAVIORAL; Name: pedometer-only; Assigned to Arm(s): pedometer-only
D: Intervention Type: BEHAVIORAL; Name: Walking 45 mins 2x p.w.; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of a Worksite Based Walking Programme on Cardiovascular Risk in Previously Sedentary Civil Servants
Brief Summary: The purpose of this study was to investigate the effects of an 8 week program of walking for 45 minutes, twice a week, on fitness, body composition , blood pressure and blood markers of cardiovascular risk. We hypothesised that this 90 minutes of walking per week would result in measurable increases in fitness and reductions in body fat, resting blood pressure and improved blood lipid profiles.


Options:
A: Arm Label: LEAP intervention; Type: EXPERIMENTAL; Interventions: Behavioral: LEAP intervention | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: LEAP intervention; Assigned to Arm(s): LEAP intervention | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Intervention Type: BEHAVIORAL; Name: Walking 45 mins 2x p.w.; Assigned to Arm(s): N/A
C: Arm Label: Physical activity treatment group; Type: EXPERIMENTAL; Interventions: Behavioral: Pedal@Work | Arm Label: Wait List Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pedal@Work Worksite Wellness | Intervention Type: BEHAVIORAL; Name: Pedal@Work Worksite Wellness; Assigned to Arm(s): Wait List Control | Intervention Type: BEHAVIORAL; Name: Pedal@Work; Assigned to Arm(s): Physical activity treatment group
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational text messaging | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational text messaging; Assigned to Arm(s): Intervention Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "The Effect of Rehabilitation of Type 2 Diabetes Mellitus Versus Standard Outpatient Care." A Randomized Controlled Trial.
Brief Summary: The aim of this study is to investigate the effect of a new rehabilitation program of type 2 diabetes patients in a primary care center versus standard care in the outpatient Hospital Clinic.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group based non-pharmacological rehabilitation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual non-pharmacological rehabilitation | Intervention Type: BEHAVIORAL; Name: Group based non-pharmacological rehabilitation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Individual non-pharmacological rehabilitation; Assigned to Arm(s): 2
B: Arm Label: The Education Health Program; Type: EXPERIMENTAL; Interventions: Behavioral: The Education Health Program | Intervention Type: BEHAVIORAL; Name: The Education Health Program; Assigned to Arm(s): The Education Health Program
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: mHealth intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: mHealth intervention; Assigned to Arm(s): Intervention Group
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "The Effect of Rehabilitation of Type 2 Diabetes Mellitus Versus Standard Outpatient Care." A Randomized Controlled Trial.
Brief Summary: The aim of this study is to investigate the effect of a new rehabilitation program of type 2 diabetes patients in a primary care center versus standard care in the outpatient Hospital Clinic.


Options:
A: Arm Label: Traditional Chinese Medicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: TCM | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TCM; Assigned to Arm(s): Traditional Chinese Medicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A
C: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group based non-pharmacological rehabilitation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual non-pharmacological rehabilitation | Intervention Type: BEHAVIORAL; Name: Group based non-pharmacological rehabilitation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Individual non-pharmacological rehabilitation; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, National, Open-label, Prospective, Randomized Study to Evaluate Efficacy and Tolerability of Enteric-coated Mycophenolate Sodium 1440 mg/Day With Tacrolimus Reduced Dose Versus Enteric-coated Mycophenolate Sodium 720 mg/Day With Tacrolimus Standard Dose, in Maintenance, Stable, Adult, Kidney Transplant Recipients
Brief Summary: This study introduces a new optimization immunosuppressive regimen associating tacrolimus at a reduced dose and enteric-coated mycophenolate sodium at an increased dose in order to slow down renal function worsening and to prevent the progression of chronic allograft nephropathy, while maintaining the same efficacy, in maintenance renal transplant recipients.


Options:
A: Arm Label: Standard dose EC-MPS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enteric-coated mycophenolate sodium (EC-MPS), Drug: Tacrolimus, Drug: Corticosteroids | Arm Label: High EC-MPS; Type: EXPERIMENTAL; Interventions: Drug: Enteric-coated mycophenolate sodium (EC-MPS), Drug: Tacrolimus, Drug: Corticosteroids | Intervention Type: DRUG; Name: Enteric-coated mycophenolate sodium (EC-MPS); Assigned to Arm(s): High EC-MPS, Standard dose EC-MPS | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): High EC-MPS, Standard dose EC-MPS | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): High EC-MPS, Standard dose EC-MPS
B: Intervention Type: DRUG; Name: Mycophenolate mofetil withdrawal; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cyclosporione A withdrawal; Assigned to Arm(s): N/A
C: Arm Label: Low-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: High-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolic Acid (MPA), Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Mycophenolic Acid (MPA); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Cyclosporine A (CsA); Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group
D: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Brief Summary: This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.


Options:
A: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm
B: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Brief Summary: This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
B: Arm Label: E-Cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette | Arm Label: Assessments only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: E-cigarette; Assigned to Arm(s): E-Cigarette
C: Arm Label: Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Behavioral: Behavioural support | Arm Label: Patch and nicotine-free e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Behavioral: Behavioural support | Arm Label: Patch and nicotine e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Drug: Nicotine, Behavioral: Behavioural support | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DEVICE; Name: e-cigarette; Assigned to Arm(s): Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Patch and nicotine e-cigarette | Intervention Type: BEHAVIORAL; Name: Behavioural support; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Brief Summary: This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
B: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
C: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Brief Summary: This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.


Options:
A: Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Varenicline | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Sugar pill

Answer: B